Jefferies recap, FDA commissioner & Biosecure update: a BioCentury podcast

Plus, obesity: Which pharmas are in and which are out 

Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that lies ahead as a result of the U.S. elections. On the latest BioCentury This Week, BioCentury’s editors discuss how the unconventional cabinet nominations of the incoming Trump administration have cast a pall over what had been growing enthusiasm for the prospects of the biotech sector.

Washington Editor Steve Usdin also discusses what the nomination of Marty Makary as FDA commissioner could mean for the sector, and recaps the latest update on the BioSecure Act.

In addition, the BioCentury team discusses which major pharmas are diving in, dipping toes or sitting out of the competition to challenge Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk (CSE:NOVO-B; NYSE:NVO) in the obesity market.